The importance of the microenvironment is highlighted by the clinical efficacy of ibrutinib which inhibits BCR signalling to disrupt trafficking of CLL cells to the lymphoid organs (Choi et al., 2016). Here, BCR is linked to B-cell chronic lymphocytic leukemia.